NEW
YORK, Sept. 18, 2019
/PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP)
(TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical
company focused on the development of oral drug delivery systems,
today announced that the company's Chief Executive Officer,
Nadav Kidron, will present and
participate in one-on-one meetings at the 2019 Ladenburg Thalmann
Healthcare Conference to be held on September 24, 2019 in New York, NY.
Details of the presentation:
Ladenburg Thalmann 2019 Healthcare
Conference
Date: September
24, 2019
Time: 3:00
– 3:25 p.m. ET
Section: Track
5 – Montmartre
Location: Sofitel,
New York, New York
Presenter: Nadav
Kidron, Chief Executive Officer
About Oramed
Oramed Pharmaceuticals is a platform technology
pioneer in the field of oral delivery solutions for drugs currently
delivered via injection. Established in 2006, with offices in
New York and Israel, Oramed has developed a novel Protein
Oral Delivery (PODTM) technology that is based on more
than 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its
proprietary lead candidate, ORMD-0801, which has the potential
to be the first commercial oral insulin capsule for the
treatment of Type 2 and Type 1 diabetes. The Company has completed
multiple Phase II clinical trials under an Investigational New Drug
application with the U.S. Food and Drug Administration. In
addition, Oramed is developing an oral GLP-1 (Glucagon-like
peptide-1) analog capsule, ORMD-0901, which has potential to
be the first orally-ingestible GLP-1 analog.
For more information, please visit www.oramed.com
Forward-looking statements: This
press release contains forward-looking statements. For example, we
are using forward-looking statements when we discuss
revolutionizing the treatment of diabetes with our products. These
forward-looking statements are based on the current expectations of
the management of Oramed only, and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements,
including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the U.S. Securities and
Exchange Commission.
Company Contact:
Oramed Pharmaceuticals
Estee Yaari
Office: +972-2-566-0001 ext. 2
US: 1 844 9 ORAMED ext. 2
Email: estee@oramed.com
View original
content:http://www.prnewswire.com/news-releases/oramed-to-present-at-ladenburg-thalmann-2019-healthcare-conference-300920460.html
SOURCE Oramed Pharmaceuticals Inc.